Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future

This paper aims to propose an update on therapeutic medical options for malignant pleural mesothelioma

Arnaud Scherpereel


Scholarcy highlights

  • The key challenge remains to find reliable predictive biomarkers for these innovative, exciting, and expensive treatments to select the best patients for each strategy
  • Arnaud Scherpereel reports grants from Roche SA and was the principal investigator of clinical trials supported by Roche
  • This article does not contain any studies with human or animal subjects performed by any of the authors
  • This article is part of the Topical Collection on Pleural Diseases and Mesothelioma

Need more features? Save interactive summary cards to your Scholarcy Library.